<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A3368663-738E-4607-A111-60039CE8C751"><gtr:id>A3368663-738E-4607-A111-60039CE8C751</gtr:id><gtr:name>European Science Foundation (ESF)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/6D82C22A-A46C-4EE3-8832-CD456259BD08"><gtr:id>6D82C22A-A46C-4EE3-8832-CD456259BD08</gtr:id><gtr:name>Acuitas Therapeutics</gtr:name><gtr:address><gtr:line1>2714 West 31st Avenue</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/EB01D9F2-5059-487D-95C4-47B11EFA06CA"><gtr:id>EB01D9F2-5059-487D-95C4-47B11EFA06CA</gtr:id><gtr:name>Quotient Bioresearch</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/0517AC0E-EF12-4F19-A6DD-6406FF2123A2"><gtr:id>0517AC0E-EF12-4F19-A6DD-6406FF2123A2</gtr:id><gtr:name>Life Technologies</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A3368663-738E-4607-A111-60039CE8C751"><gtr:id>A3368663-738E-4607-A111-60039CE8C751</gtr:id><gtr:name>European Science Foundation (ESF)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/6D82C22A-A46C-4EE3-8832-CD456259BD08"><gtr:id>6D82C22A-A46C-4EE3-8832-CD456259BD08</gtr:id><gtr:name>Acuitas Therapeutics</gtr:name><gtr:address><gtr:line1>2714 West 31st Avenue</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/EB01D9F2-5059-487D-95C4-47B11EFA06CA"><gtr:id>EB01D9F2-5059-487D-95C4-47B11EFA06CA</gtr:id><gtr:name>Quotient Bioresearch</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/0517AC0E-EF12-4F19-A6DD-6406FF2123A2"><gtr:id>0517AC0E-EF12-4F19-A6DD-6406FF2123A2</gtr:id><gtr:name>Life Technologies</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/511861E9-7AE9-41FC-8ABE-B0AC7470B0CB"><gtr:id>511861E9-7AE9-41FC-8ABE-B0AC7470B0CB</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>Stuart</gtr:otherNames><gtr:surname>Owen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4332AC26-1431-4073-9A18-6DEE6C703978"><gtr:id>4332AC26-1431-4073-9A18-6DEE6C703978</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:otherNames>Paul</gtr:otherNames><gtr:surname>Simons</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F67F926F-C3CA-44B6-AA86-9C74A30BE428"><gtr:id>F67F926F-C3CA-44B6-AA86-9C74A30BE428</gtr:id><gtr:firstName>Bernard</gtr:firstName><gtr:otherNames>Chong</gtr:otherNames><gtr:surname>Khoo</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0802469"><gtr:id>F6B6B41D-DDFA-4AD6-917A-9EE0648A9280</gtr:id><gtr:title>Lowering LDL cholesterol levels by antisense oligonucleotide induced alternative splicing of Apolipoprotein B</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0802469</gtr:grantReference><gtr:abstractText>People with high levels of cholesterol are at higher risk of having heart attacks and strokes. Treatments that lower the levels of cholesterol have been shown to protect against these diseases, thereby saving lives. This project will look into how we can use a new drug called an antisense oligonucleotide to lower the level of cholesterol in the blood and therefore perhaps to reduce the risk of heart attacks and strokes.</gtr:abstractText><gtr:technicalSummary>Hypercholesterolaemia and high LDL levels cause cardiovascular disease, the major killer in the developed world. Currently licensed treatments for hypercholesterolaemia have many shortcomings: there is a need for alternative therapies to lower cholesterol. Altering the expression of Apolipoprotein B (APOB) has emerged as a key method to accomplish this goal. APOB is the principal structural apolipoprotein in LDL, VLDL, IDL and chylomicron particles. Antisense oligonucleotides (ASOs) which induce alternative splicing of APOB exon 27 are able to generate a truncated APOB isoform, APOB87(SKIP27). Truncation of APOB100, as seen in patients with hypobetalipoproteinaemia, causes major reductions in total and LDL cholesterol levels. ASO-induced alternative splicing will be a useful therapy to reduce circulating LDL and cholesterol levels, without the drawbacks associated with methods that generally down-regulate all isoforms of APOB. In this project, we propose to: (1) optimize the configuration of ASOs and the skipping effect in vitro; and (2) assess the effects of injected optimized ASO on circulating LDL and cholesterol levels in a transgenic mouse model of hypercholesterolaemia and atherosclerosis. Completion of these objectives would validate this ASO-based compound as a therapy for hypercholesterolaemia.</gtr:technicalSummary><gtr:fund><gtr:end>2011-11-09</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-08-10</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>604980</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Science Foundation (ESF)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:department>European Cooperation in Science and Technology (COST)</gtr:department><gtr:description>COST Network for Exon Skipping</gtr:description><gtr:id>A66024C8-B12C-463E-8A2B-AF2FA17C12A2</gtr:id><gtr:impact>We have made contact with potential collaborators regarding SSO deliver.</gtr:impact><gtr:partnerContribution>THis network allows access to partner expertise on topics relating to therapeutic development of antisense oligonucleotides for exon skipping</gtr:partnerContribution><gtr:piContribution>Dr Bernard Khoo and Dr Petra Disterer have been elected to the COST Action BM1207 (for exon skipping)</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Acuitas Therapeutics</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Collaboration with Acuitas Tx</gtr:description><gtr:id>88C6F692-2AFE-40F1-B299-9AFA97529CA1</gtr:id><gtr:impact>Project is still on-going</gtr:impact><gtr:partnerContribution>Acuitas is formulating the APO-skip SSOs in their lipid nanoparticles (previously used in human trials).</gtr:partnerContribution><gtr:piContribution>We are providing APO-skip SSOs for formulation testing and will be testing the formulations in human APOB mice.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Life Technologies</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Delivery of Antisense Oligonucleotides to Liver</gtr:description><gtr:id>85D63380-96CD-49BC-BD7F-6E63CEDB4EED</gtr:id><gtr:impact>Experiments in progress</gtr:impact><gtr:partnerContribution>Life Technologies are developing new formulations for delivery of antisense oligonucleotides. Contribution: new Invivofectamine formulations.</gtr:partnerContribution><gtr:piContribution>We are supplying the splice-switching oligonucleotides and testing these in transgenic mice.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Quotient Bioresearch</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Bioanalytical Sciences</gtr:department><gtr:description>Methods for detection of oligonucleotides and APOB isoforms</gtr:description><gtr:id>EFE56D77-4521-4B7E-90B5-9154D51930FC</gtr:id><gtr:impact>Experiments in progress</gtr:impact><gtr:partnerContribution>Development of mass-spectrometry methods to detect oligonucleotides and APOB isoforms</gtr:partnerContribution><gtr:piContribution>We are supplying materials (oligonucleotides, plasma samples)</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>41017</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCL Business (UCLB)</gtr:department><gtr:description>Proof-of-Concept Funding</gtr:description><gtr:end>2012-05-02</gtr:end><gtr:fundingOrg>University College London (UCL)</gtr:fundingOrg><gtr:id>C866C970-A93E-458A-A4A9-D3D4297B3D89</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25205</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCL Business (UCLB)</gtr:department><gtr:description>Proof-of-Concept Funding</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>University College London (UCL)</gtr:fundingOrg><gtr:id>63A3F13A-49F9-4604-99DB-DAD78924733F</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention concerns the use of an antisense oligonucleotide (ASO) to induce alternative splicing of Apolipoprotein B (APOB) by skipping exon 27. This is intended to truncate APOB100 expression and to lower LDL cholesterol for therapeutic purposes.

INVENTIONS PATENTED
1. The concept of 'triple-targeting' three splice elements with a single ASO or combinations of ASOs (5' splice site, 3' splice site, branchpoint sequence) to increase exon skipping efficiency.
2. A new antisense oligonucleotide sequence for efficiently inducing APOB exon 27 skipping: s27_53B4.
3. The use of 5' fluoresceination of ASOs to increase exon skipping efficiency of ASOs.
4. The use of partial phosphorothioate backbone modification to increase exon skipping efficiency of ASOs.
5. The combination of any, or all of these modifications to increase exon skipping efficiency of ASOs.</gtr:description><gtr:id>79E3967B-C2BA-4F0F-BF78-567BCED6720C</gtr:id><gtr:impact>N/A</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>GB1117880.3</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Truncation of Apolipoprotein B100 with antisense oligonucleotides</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Pre-clinical lead identified from cellular assays. In testing in animals.</gtr:description><gtr:id>CAA9736D-3291-4957-8D54-A28364FD8288</gtr:id><gtr:impact>New technologies relating to modification of antisense oligonucleotides to increase efficiency in exon skipping identified.</gtr:impact><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Antisense oligonucleotide to cause APOB exon 27 skipping</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C141FBE1-0383-44D2-94EF-75A553EB1540"><gtr:id>C141FBE1-0383-44D2-94EF-75A553EB1540</gtr:id><gtr:title>Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/039a48a20e25d01f50eb5a59d6fc219d"><gtr:id>039a48a20e25d01f50eb5a59d6fc219d</gtr:id><gtr:otherNames>Disterer P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2CB2ACCD-E931-4530-BB59-0FFDF711CFC5"><gtr:id>2CB2ACCD-E931-4530-BB59-0FFDF711CFC5</gtr:id><gtr:title>Genetic therapies to lower cholesterol.</gtr:title><gtr:parentPublicationTitle>Vascular pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3ec18ee02f0acb4e05c242d08d33926c"><gtr:id>3ec18ee02f0acb4e05c242d08d33926c</gtr:id><gtr:otherNames>Khoo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1537-1891</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BA6A766B-F329-4BE6-8348-30DC358B07A7"><gtr:id>BA6A766B-F329-4BE6-8348-30DC358B07A7</gtr:id><gtr:title>Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB.</gtr:title><gtr:parentPublicationTitle>BMC molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3ec18ee02f0acb4e05c242d08d33926c"><gtr:id>3ec18ee02f0acb4e05c242d08d33926c</gtr:id><gtr:otherNames>Khoo B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1471-2199</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C9CF83D9-C6F3-4FAB-A86F-01FEC2B433D1"><gtr:id>C9CF83D9-C6F3-4FAB-A86F-01FEC2B433D1</gtr:id><gtr:title>Antisense-mediated exon-skipping to induce gene knockdown.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/039a48a20e25d01f50eb5a59d6fc219d"><gtr:id>039a48a20e25d01f50eb5a59d6fc219d</gtr:id><gtr:otherNames>Disterer P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802469</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>